Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) FCF Margin (2018 - 2025)

BioNexus Gene Lab's FCF Margin history spans 8 years, with the latest figure at 198.46% for Q4 2025.

  • Quarterly results put FCF Margin at 198.46% for Q4 2025, up 18994.0% from a year ago — trailing twelve months through Dec 2025 was 25.26% (down 86.0% YoY), and the annual figure for FY2025 was 25.26%, down 86.0%.
  • FCF Margin for Q4 2025 was 198.46% at BioNexus Gene Lab, up from 48.86% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 198.46% in Q4 2025 to a low of 68.52% in Q3 2024.
  • The 5-year median for FCF Margin is 3.73% (2023), against an average of 4.27%.
  • The sharpest move saw FCF Margin plummeted -5066bps in 2023, then soared 18994bps in 2025.
  • Year by year, FCF Margin stood at 14.84% in 2021, then rose by 9bps to 16.19% in 2022, then crashed by -313bps to 34.47% in 2023, then skyrocketed by 125bps to 8.53% in 2024, then soared by 2228bps to 198.46% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 198.46%, 48.86%, and 33.6% for Q4 2025, Q3 2025, and Q2 2025 respectively.